Peter Zage, M.D., Ph.D.


3020 Children's Way
MC 5035
San Diego, CA 92123




Rady Children's Specialists of San Diego

Medical Group / IPA

Rady Children's Specialists

Medical School

Columbia University College of Physicians and Surgeons


University of Chicago Comer Children's Hospital


Children's Memorial Hospital

Board Certifications

Pediatric Hematology/Oncology




Dr. Peter Zage is an attending hematologist/oncologist at Rady Children's Hospital-San Diego and an associate professor-in-residence in pediatric oncology at UC San Diego Moores Cancer Center.

Dr. Zage received his bachelor's degree in biology from Johns Hopkins University and earned his medical and doctoral degrees from Columbia University in New York. He then completed a residency in pediatrics at the University of Chicago Children's Hospital and a fellowship in pediatric hematology/oncology at Children's Memorial Hospital (now Lurie Children's Hospital) before starting his first faculty position as an assistant professor at the University of Texas MD Anderson Cancer Center. He was an assistant professor in the Section of Pediatric Hematology/Oncology at Baylor College of Medicine and Texas Children's Cancer Center prior to joining Rady Children's and UC San Diego in 2016.

Dr. Zage is an expert in the treatment of the pediatric solid tumors neuroblastoma and retinoblastoma, and his laboratory is focused on developing novel treatments and identifying novel targets for therapies for children with solid tumors. His primary laboratory projects include studies to better understand the pathways involved in the regulation of growth factor receptor trafficking and degradation in tumor cells and their role in tumor growth and treatment response in addition to studies to identify novel therapeutic targets and novel agents to use in combination with established therapies.

Dr. Zage's laboratory has identified a key role for the ubiquitin ligase UBE4B in the regulation of receptor trafficking in neuroblastoma tumor cells, and he has also identified several promising novel targeted agents that have been translated into early phase clinical trials for children with relapsed and refractory solid tumors.


The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.
Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.
Zage PE, Whittle SB, Shohet JM

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.
Du M, Zhang L, Scorsone KA, Woodfield SE, Zage PE

Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Woodfield SE, Guo RJ, Liu Y, Major AM, Hollingsworth EF, Indiviglio S, Whittle SB, Mo Q, Bean AJ, Ittmann M, Lopez-Terrada D, Zage PE

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE

A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, Ittmann M, Scheurer ME, Bean AJ, Zage PE

Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L, Scorsone K, Woodfield SE, Zage PE

CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.
Zhang L, Agarwal S, Shohet JM, Zage PE

mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J, Xu X, Liu W, Guan S, Chen Z, shi Y, Patel R, Vasudevan SA, Zage PE, Zhang H, Nuchtern JG, Kim ES, Fu S, Yang J

The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE

Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
Brown BS, Patanam T, Mobli K, Celia C, Zage PE, Bean AJ, Tasciotti E

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.
Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL

UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation.
Sirisaengtaksin N, Gireud M, Yan Q, Kubota Y, Meza D, Waymire JC, Zage PE, Bean AJ

Congenital neuroblastoma in a neonate with isotretinoin embryopathy.
Aguilar S, Louis C, Hicks J, Zage P, Russell H

UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DP, Bean AJ

New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.
Zage PE, Louis CU, Cohn SL

Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.
Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, Kuttesch J, Ketonen L, Mahajan A

Notch pathway activation induces neuroblastoma tumor cell growth arrest.
Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA

Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations.
Stephen MD, Zage PE, Waguespack SG

Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells.
Singh A, Rokes C, Gireud M, Fletcher S, Baumgartner J, Fuller G, Stewart J, Zage P, Gopalakrishnan V

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.
Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA

Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V

Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP

A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.